{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T21:20:57Z","timestamp":1782768057026,"version":"3.54.5"},"reference-count":57,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008672","name":"Wilhelm Sander Foundation","doi-asserted-by":"publisher","award":["2024.018.1"],"award-info":[{"award-number":["2024.018.1"]}],"id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Young Talents in Clinical Research"},{"DOI":"10.13039\/501100008485","name":"Swiss Academy of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008485","id-type":"DOI","asserted-by":"publisher"}]},{"name":"G. & J. Bangerter-Rhyner Foundation, Switzerland","award":["2022_EKFKSE.03"],"award-info":[{"award-number":["2022_EKFKSE.03"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Pheochromocytomas and paragangliomas (PPGL) are rare endocrine tumors with high heritability. Carriers of pathogenic variants (PVs) in susceptibility genes face a lifelong risk of recurrence or metastatic disease. Quality of life (QoL) in patients with PPGL, a history of PPGL and PV carriers, remains insufficiently studied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We assessed patient-reported QoL in patients with PPGL before and after surgery and in carriers of susceptibility PVs for the development of PPGLs within the prospective ProsPheo study. QoL was evaluated using standardized questionnaires (SF-12, PHQ-D, and GAD-7).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 202 participants were analyzed. SF-12 physical component summary scores (PCS) differed significantly across subgroups (P = .006), with the lowest PCS scores in patients with metastatic PPGL (40.3) and unresected head and neck paragangliomas (HNPGL) (40.0), compared with PV carriers after curative PPGL resection (50.2). Within metastatic disease, hormonally active tumors showed lower PCS scores than inactive tumors (36.9 vs 46.2; P = .03). Perceived physical health in carriers of a PV without history of a PPGL was significantly lower compared to the age-matched general population. Mental health was not significantly impaired across all subgroups. Clinically relevant anxiety was reported in 15.2% of PV carriers and 21.7% of patients with unresected HNPGLs, compared with about 5.9% in the general population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patient-reported physical health was reduced in patients with metastatic PPGLs, unresected HNPGLs, and PV carriers without prior PPGL, whereas patients after curative PPGL resection reported QoL comparable to the general population, regardless of PV status, suggesting that annual follow-up has minimal impact on QoL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejendo\/lvag003","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T12:51:06Z","timestamp":1767963066000},"page":"80-90","source":"Crossref","is-referenced-by-count":2,"title":["Quality of life in patients with pheochromocytoma and paraganglioma: influence of tumor type, genetics and surgical resection"],"prefix":"10.1093","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4555-8334","authenticated-orcid":false,"given":"Alessa","family":"Fischer","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ), and University of Zurich (UZH) , Zurich CH-8091 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3499-5910","authenticated-orcid":false,"given":"Hanna","family":"Remde","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of W\u00fcrzburg , Wurzburg 97080 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0772-1604","authenticated-orcid":false,"given":"Christina","family":"Pamporaki","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden , Dresden 01307 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Prinzi","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Department of Clinical and Experimental Medicine, University of Catania, Garibaldi-Nesima Medical Center , Catania 95122 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8283-7861","authenticated-orcid":false,"given":"Otilia","family":"Kimpel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of W\u00fcrzburg , Wurzburg 97080 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"K\u00fcppers","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of W\u00fcrzburg , Wurzburg 97080 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8906-2563","authenticated-orcid":false,"given":"Constanze","family":"Hantel","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ), and University of Zurich (UZH) , Zurich CH-8091 ,","place":["Switzerland"]},{"name":"Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden , Dresden 01307 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3541-3767","authenticated-orcid":false,"given":"Karel","family":"Pacak","sequence":"additional","affiliation":[{"name":"Center for Adrenal Endocrine Tumors, AKESO , Prague 5 155 00 ,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1176-6186","authenticated-orcid":false,"given":"Ashley B","family":"Grossman","sequence":"additional","affiliation":[{"name":"Green Templeton College, University of Oxford , Oxford OX2 6HG ,","place":["United Kingdom"]},{"name":"NET Unit, ENETS Centre of Excellence, Royal Free Hospital , London NW3 2QG ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7826-3984","authenticated-orcid":false,"given":"Felix","family":"Beuschlein","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ), and University of Zurich (UZH) , Zurich CH-8091 ,","place":["Switzerland"]},{"name":"Department of Medicine IV, University Hospital, Ludwig-Maximilians-University Munich , Munich 80336 ,","place":["Germany"]},{"name":"The LOOP Zurich\u2014Medical Research Center , University of Zurich, Zurich 8044 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6170-6398","authenticated-orcid":false,"given":"Martin","family":"Fassnacht","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of W\u00fcrzburg , Wurzburg 97080 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7064-590X","authenticated-orcid":false,"given":"Svenja","family":"N\u00f6lting","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ), and University of Zurich (UZH) , Zurich CH-8091 ,","place":["Switzerland"]},{"name":"Department of Medicine IV, University Hospital, Ludwig-Maximilians-University Munich , Munich 80336 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"issue":"1","key":"2026030204012422300_lvag003-B1","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s12022-022-09704-6","article-title":"Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas","volume":"33","author":"Mete","year":"2022","journal-title":"Endocr Pathol"},{"issue":"2","key":"2026030204012422300_lvag003-B2","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nrc3648","article-title":"Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity","volume":"14","author":"Dahia","year":"2014","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"2026030204012422300_lvag003-B3","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1210\/jc.2018-01968","article-title":"Prognosis of malignant pheochromocytoma and paraganglioma (MAPP-Prono Study): a European network for the study of adrenal tumors retrospective study","volume":"104","author":"Hescot","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026030204012422300_lvag003-B4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Comprehensive molecular characterization of pheochromocytoma and paraganglioma","volume":"31","author":"Fishbein","year":"2017","journal-title":"Cancer Cell"},{"issue":"1","key":"2026030204012422300_lvag003-B5","doi-asserted-by":"publisher","first-page":"6262","DOI":"10.1038\/s41467-022-34011-3","article-title":"Single-nuclei and bulk-tissue gene-expression analysis of pheochromocytoma and paraganglioma links disease subtypes with tumor microenvironment","volume":"13","author":"Zethoven","year":"2022","journal-title":"Nat Commun"},{"issue":"8","key":"2026030204012422300_lvag003-B6","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1097\/HJH.0000000000002438","article-title":"Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension","volume":"38","author":"Lenders","year":"2020","journal-title":"J Hypertens."},{"issue":"1","key":"2026030204012422300_lvag003-B7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1677\/ERC-10-0211","article-title":"Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma","volume":"18","author":"Eisenhofer","year":"2011","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"2026030204012422300_lvag003-B8","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1530\/EJE-19-0159","article-title":"Pheochromocytoma and paraganglioma: clinical feature-based disease probability in relation to catecholamine biochemistry and reason for disease suspicion","volume":"181","author":"Geroula","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2026030204012422300_lvag003-B9","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/MPA.0000000000001792","article-title":"The North American neuroendocrine tumor society consensus guidelines for surveillance and management of metastatic and\/or unresectable pheochromocytoma and paraganglioma","volume":"50","author":"Fishbein","year":"2021","journal-title":"Pancreas"},{"issue":"5","key":"2026030204012422300_lvag003-B10","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-16-0033","article-title":"European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma","volume":"174","author":"Plouin","year":"2016","journal-title":"Eur J Endocrinol."},{"issue":"2","key":"2026030204012422300_lvag003-B11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1210\/endrev\/bnab019","article-title":"Personalized management of pheochromocytoma and paraganglioma","volume":"43","author":"Nolting","year":"2022","journal-title":"Endocr Rev"},{"issue":"3","key":"2026030204012422300_lvag003-B12","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41574-023-00926-0","article-title":"Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert Consensus statement","volume":"20","author":"Taieb","year":"2024","journal-title":"Nat Rev Endocrinol"},{"issue":"10","key":"2026030204012422300_lvag003-B13","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1210\/clinem\/dgad166","article-title":"Metastatic pheochromocytoma and paraganglioma: somatostatin receptor 2 expression, genetics, and therapeutic responses","volume":"108","author":"Fischer","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026030204012422300_lvag003-B14","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1210\/jc.2010-1946","article-title":"Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators","volume":"96","author":"Ayala-Ramirez","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026030204012422300_lvag003-B15","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1210\/clinem\/dgac677","article-title":"TNM staging and overall survival in patients with pheochromocytoma and sympathetic paraganglioma","volume":"108","author":"Jimenez","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026030204012422300_lvag003-B16","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1210\/jc.2012-3625","article-title":"Changes in energy metabolism in pheochromocytoma","volume":"98","author":"Petr\u00e1k","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2026030204012422300_lvag003-B17","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/cen.12536","article-title":"Hypertension and hypertensive cardiomyopathy in patients with a relapse-free history of phaeochromocytoma","volume":"82","author":"Weismann","year":"2015","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"9","key":"2026030204012422300_lvag003-B18","doi-asserted-by":"publisher","first-page":"e2966","DOI":"10.1210\/clinem\/dgae901","article-title":"Long-term persistence of glycemic dysregulation in patients with a history of pheochromocytoma\/paraganglioma","volume":"110","author":"Fischer","year":"2025","journal-title":"J Clin Endocrinol Metab."},{"issue":"Suppl 3","key":"2026030204012422300_lvag003-B19","doi-asserted-by":"publisher","first-page":"A70.1","DOI":"10.1136\/heartjnl-2014-306118.122","article-title":"122 cardiac abnormalities are common in patients diagnosed with phaeochromocytoma as detected by cardiovascular magnetic resonance imaging","volume":"100","author":"Ferreira","year":"2014","journal-title":"Heart"},{"issue":"1","key":"2026030204012422300_lvag003-B20","doi-asserted-by":"publisher","first-page":"e316","DOI":"10.1210\/clinem\/dgaa760","article-title":"Quality of life in patients with neuroendocrine neoplasms: the role of severity, clinical heterogeneity, and resilience","volume":"106","author":"Scandurra","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026030204012422300_lvag003-B21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1477-7525-5-18","article-title":"Health related quality of life and psychosocial function among patients with carcinoid tumours. A longitudinal, prospective, and comparative study","volume":"5","author":"Fr\u00f6jd","year":"2007","journal-title":"Health Qual Life Outcomes"},{"issue":"7","key":"2026030204012422300_lvag003-B22","doi-asserted-by":"publisher","first-page":"R267","DOI":"10.1530\/ERC-20-0066","article-title":"Health-related quality of life in neuroendocrine neoplasia: a critical review","volume":"27","author":"White","year":"2020","journal-title":"Endocr Relat Cancer."},{"issue":"5","key":"2026030204012422300_lvag003-B23","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1530\/EJE-12-0968","article-title":"Quality of life is decreased in patients with paragangliomas","volume":"168","author":"Van Hulsteijn","year":"2013","journal-title":"Eur J Endocrinol."},{"issue":"2","key":"2026030204012422300_lvag003-B24","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1530\/EJE-07-0464","article-title":"Reduced quality of life in patients with head-and-neck paragangliomas","volume":"158","author":"Havekes","year":"2008","journal-title":"Eur J Endocrinol."},{"issue":"6","key":"2026030204012422300_lvag003-B25","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1177\/1708538119848522","article-title":"Assessment of health-related quality of life in patients prior to carotid body tumor resection","volume":"27","author":"Garcia-Alva","year":"2019","journal-title":"Vascular"},{"issue":"3","key":"2026030204012422300_lvag003-B26","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/00005650-199603000-00003","article-title":"A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity","volume":"34","author":"Ware","year":"1996","journal-title":"Med Care"},{"key":"2026030204012422300_lvag003-B27","volume-title":"SF-12: how to Score the SF-12 Physical and Mental Health Summary Scales","author":"Ware","year":"1995"},{"issue":"11","key":"2026030204012422300_lvag003-B28","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/s0895-4356(98)00109-7","article-title":"Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment","volume":"51","author":"Gandek","year":"1998","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"2026030204012422300_lvag003-B29","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/oxfordjournals.pubmed.a024606","article-title":"A shorter form health survey: can the SF-12 replicate results from the SF-36 in longitudinal studies?","volume":"19","author":"Jenkinson","year":"1997","journal-title":"J Public Health Med"},{"issue":"1-3","key":"2026030204012422300_lvag003-B30","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jad.2008.06.026","article-title":"The PHQ-8 as a measure of current depression in the general population","volume":"114","author":"Kroenke","year":"2009","journal-title":"J Affect Disord."},{"issue":"9","key":"2026030204012422300_lvag003-B31","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med"},{"issue":"1","key":"2026030204012422300_lvag003-B32","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0165-0327(03)00198-8","article-title":"Measuring depression outcome with a brief self-report instrument: sensitivity to change of the Patient Health Questionnaire (PHQ-9)","volume":"81","author":"L\u00f6we","year":"2004","journal-title":"J Affect Disord."},{"issue":"3","key":"2026030204012422300_lvag003-B33","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/MLR.0b013e318160d093","article-title":"Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population","volume":"46","author":"Lowe","year":"2008","journal-title":"Med Care"},{"issue":"15","key":"2026030204012422300_lvag003-B34","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1200\/JCO.2013.52.4611","article-title":"Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an American Society of Clinical Oncology guideline adaptation","volume":"32","author":"Andersen","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026030204012422300_lvag003-B35","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","article-title":"A new method for measuring daytime sleepiness: the Epworth sleepiness scale","volume":"14","author":"Johns","year":"1991","journal-title":"Sleep"},{"key":"2026030204012422300_lvag003-B36","volume-title":"R: A Language and Environment for Statistical Computing","year":"2025"},{"issue":"1","key":"2026030204012422300_lvag003-B37","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3790\/schm.127.1.171","article-title":"Computation of standard values for physical and mental health scale scores using the SOEP version of SF-12v2","volume":"127","author":"Andersen","year":"2007","journal-title":"J Appl Soc Sci Stud"},{"key":"2026030204012422300_lvag003-B38","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jad.2016.12.012","article-title":"Psychometric evaluation of the Generalized Anxiety Disorder Screener GAD-7, based on a large German general population sample","volume":"210","author":"Hinz","year":"2017","journal-title":"J Affect Disord"},{"issue":"5","key":"2026030204012422300_lvag003-B39","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.genhosppsych.2013.04.006","article-title":"Standardization of the depression screener patient health questionnaire (PHQ-9) in the general population","volume":"35","author":"Kocalevent","year":"2013","journal-title":"Gen Hosp Psychiatry"},{"key":"2026030204012422300_lvag003-B40","volume-title":"Entwicklung eines Verfahrens zur Berechnung der k\u00f6rperlichen und psychischen Summenskalen auf Basis der SOEP\u2014Version des SF 12 (Algorithmus)","author":"N\u00fcbling","year":"2006"},{"issue":"9","key":"2026030204012422300_lvag003-B41","doi-asserted-by":"publisher","first-page":"6371","DOI":"10.1007\/s00432-023-04600-w","article-title":"Prevalence and severity of anxiety in cancer patients: results from a multi-center cohort study in Germany","volume":"149","author":"Goerling","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026030204012422300_lvag003-B42","doi-asserted-by":"publisher","first-page":"1526181","DOI":"10.3389\/fpsyg.2025.1526181","article-title":"Psychometric evaluation and community norms of the GAD-7, based on a representative German sample","volume":"16","author":"Kliem","year":"2025","journal-title":"Front Psychol"},{"issue":"2","key":"2026030204012422300_lvag003-B43","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s10147-024-02659-0","article-title":"Relationship between patient-reported health-related quality of life as measured with the SF-36 or SF-12 and their mortality risk in patients with diverse cancer type: a meta-analysis","volume":"30","author":"Tanaka","year":"2025","journal-title":"Int J Clin Oncol"},{"issue":"5","key":"2026030204012422300_lvag003-B44","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1093\/ejendo\/lvad146","article-title":"Responses to systemic therapy in metastatic pheochromocytoma\/paraganglioma: a retrospective multicenter cohort study","volume":"189","author":"Fischer","year":"2023","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026030204012422300_lvag003-B45","doi-asserted-by":"publisher","first-page":"101977","DOI":"10.1016\/j.beem.2025.101977","article-title":"Systemic therapy for patients with metastatic pheochromocytoma and paraganglioma","volume":"39","author":"Fischer","year":"2025","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"12","key":"2026030204012422300_lvag003-B46","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41574-024-01024-5","article-title":"International consensus statement on the diagnosis and management of phaeochromocytoma and paraganglioma in children and adolescents","volume":"20","author":"Casey","year":"2024","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"2026030204012422300_lvag003-B47","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1530\/ERC-21-0359","article-title":"Head\/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine","volume":"29","author":"Richter","year":"2022","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"2026030204012422300_lvag003-B48","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s12020-025-04167-1","article-title":"Pros and cons of surgical versus conservative management for head and neck paraganglioma: a real-world data analysis","volume":"88","author":"Canu","year":"2025","journal-title":"Endocrine"},{"issue":"3","key":"2026030204012422300_lvag003-B49","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/ejendo\/lvaf033","article-title":"Low psychosocial burden in patients with paraganglioma syndrome: results from the Head and Neck Paraganglioma Registry in a single center","volume":"192","author":"de Bresser","year":"2025","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2026030204012422300_lvag003-B50","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1007\/s13187-019-01562-x","article-title":"Psychometric properties of the MICRA questionnaire in Portuguese individuals carrying SDHx mutations","volume":"35","author":"Martins","year":"2020","journal-title":"J Canc Educ"},{"issue":"10","key":"2026030204012422300_lvag003-B51","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1037\/hea0000993","article-title":"Pheochromocytoma and paraganglioma genetic testing: psychological impact","volume":"39","author":"Martins","year":"2020","journal-title":"Health Psychol"},{"issue":"2","key":"2026030204012422300_lvag003-B52","doi-asserted-by":"publisher","first-page":"T69","DOI":"10.1530\/ERC-17-0335","article-title":"Patient quality of life and prognosis in multiple endocrine neoplasia type 2","volume":"25","author":"Grey","year":"2018","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"2026030204012422300_lvag003-B53","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1089\/thy.2016.0148","article-title":"Assessment of depression, anxiety, quality of life, and coping in long-standing multiple endocrine neoplasia type 2 patients","volume":"27","author":"Rodrigues","year":"2017","journal-title":"Thyroid"},{"issue":"6","key":"2026030204012422300_lvag003-B54","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1210\/js.2018-00371","article-title":"Quality of life and coping in multiple endocrine neoplasia type 2","volume":"3","author":"Correa","year":"2019","journal-title":"J Endocr Soc"},{"issue":"9-10","key":"2026030204012422300_lvag003-B55","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1515\/jpem-2013-0369","article-title":"Counseling patients with succinate dehydrogenase subunit defects: genetics, preventive guidelines, and dealing with uncertainty","volume":"27","author":"Raygada","year":"2014","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"5","key":"2026030204012422300_lvag003-B56","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S2213-8587(23)00038-4","article-title":"Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants","volume":"11","author":"Taieb","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"2026030204012422300_lvag003-B57","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1177\/0194599820915490","article-title":"British skull base society clinical consensus document on management of head and neck paragangliomas","volume":"163","author":"Lloyd","year":"2020","journal-title":"Otolaryngol Head Neck Surg"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvag003\/66379164\/lvag003.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/194\/2\/80\/66379164\/lvag003.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/194\/2\/80\/66379164\/lvag003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T09:01:36Z","timestamp":1772442096000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/194\/2\/80\/8423043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvag003","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,12]]}}}